Drug Type CAR-T |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-cell lymphoma refractory | Phase 1 | China | 17 Mar 2021 | |
Refractory Leukemia | Phase 1 | China | 17 Mar 2021 |